First Tracks Biotherapeutics (NASDAQ:TRAX) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of First Tracks Biotherapeutics (NASDAQ:TRAX) have been given a consensus rating of “Moderate Buy” by the nine analysts that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a hold rating and eight have issued a buy rating on the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $47.8750.

Several research firms recently issued reports on TRAX. HC Wainwright raised their price objective on shares of First Tracks Biotherapeutics from $30.00 to $44.00 and gave the stock a “buy” rating in a research report on Friday, July 10th. Wedbush boosted their target price on shares of First Tracks Biotherapeutics from $30.00 to $60.00 and gave the company an “outperform” rating in a report on Tuesday, July 28th. UBS Group started coverage on shares of First Tracks Biotherapeutics in a report on Tuesday, April 21st. They set a “buy” rating and a $45.00 price target for the company. Wells Fargo & Company lifted their price target on shares of First Tracks Biotherapeutics from $30.00 to $55.00 and gave the company an “overweight” rating in a research report on Tuesday, July 28th. Finally, Wall Street Zen raised First Tracks Biotherapeutics to a “hold” rating in a research note on Saturday, May 2nd.

First Tracks Biotherapeutics Trading Up 2.0%

Shares of NASDAQ:TRAX opened at $46.95 on Thursday. First Tracks Biotherapeutics has a 52-week low of $14.72 and a 52-week high of $49.58. The stock has a market cap of $1.64 billion and a PE ratio of -25.52. The company has a fifty day moving average of $26.32.

First Tracks Biotherapeutics is a healthcare company in the Biotechnology industry.